A B S T R A C T The interrelationship between apolipoprotein B in very low density lipoprotein (VLDL-B) and in low density lipoprotein (LDL-B) was studied in seven normal and hyperlipidemic men and women, with purified radioiodinated VLDL. The time-course of the appearance of radioactivity in LDL was followed. As the specific activity curves intersected at the maximal height of the LDL-B curve, it was inferred that all or most LDL-B peptide is derived from VLDL-B peptide.
INTRODUCTION
The lipoproteins of plasma comprise a broad spectrum of molecules varying in size and in lipid and protein content. These lipoproteins have been classified, chiefly operationally, into four major classes, but there is growing evidence that these lipoproteins form a dynamic system within which exchange and mass transfer of lipid and protein content occur. The origin of these lipoproteins has been a matter of extensive research and it has been shown that very low density lipoprotein VLDL)1 is secreted by the liver and small intestine (2) in nascent form (3) . Similarly it has been shown that high density lipoprotein is secreted by the liver and small intestine (2, 4) in nascent form.
On the other hand, the origin of low density lipoprotein (LDL) is less clear. Graham et al. (5) showed that heparin injection into rabbits and humans induced a fall in plasma lipoproteins of Sf 20-400 and a concomitant rise in the level of lipoproteins of Sf 12-20. Similar changes were found in vitro after incubation of VLDL with postheparin plasma (6). Gitlin et al. (7) injected radioiodinated VLDL of St 10-100 into human subjects and observed that a significant proportion of label appeared in LDL. Similarly, LDL triglyceride appears to be derived from VLDL in rabbits (8) and humans (9) .
The protein moiety in VLDL (apo VLDL) consists of several different peptides including apolipoprotein B, which constitutes about 50% of apo VLDL (10) . This B peptide in VLDL is identical to the major peptide of LDL. Bilheimer et al. (11) have shown in 1Abbrez,iations used in this paper: FCR, fractional catabolic rate; LDL, low density lipoproteins; U/P ratio, urinary radioactivity/plasma radioactivity; VLDL, very low density lipoproteins.
The Jouirnal of Clinical Investigation Volutme 56 December 1975 1481-1490 148A1 vivo using radioiodinated VLDL that a proportion of the radiolabeled B peptide of VLDL appears in the LDL fraction, first into the d 1.006-1.019 range and later into the d 1.019-1.063 range; specific activity data were not obtained in this study.
In the present investigation the interrelationship between the B peptide (apo B) in VLDL and LDL was quantitatively studied to elucidate what proportion of B peptide in LDL is derived from VLDL and what proportion of VLDL mass is converted into LDL.
For this purpose radioiodinated VLDL was reinjected into human subjects and specific activity curves for VLDL-B and LDL-B peptide were obtained (study A). By simultaneous injection of VLDL and LDL, labeled with different iodine isotopes, the transfer of VLDL-B peptide into LDL-B peptide was quantitated (study B) and the turnover rates of VLDL-B and LDL-B peptides were compared (study C).
METHODS Subjects
Study A. Four men and three women were studied. Three subjects had normal blood lipid concentrations. Three subjects had primary endogenous hypertriglyceridemia, known underlying causes being excluded; two had prebetaliyperlipoproteinemia (type IV), and one also had chylomicronemia (type V). One subject with heterozygous familial hypercholesterolemia (type IIa) was studied. The diagnosis was based on an elevated plasma LDL cholesterol concentration, the presence of tendon xanthomata, and an affected first-degree relative. Normal levels for cholesterol and triglyceride were defined as below 95th percentile as found in a London population (12) . Study B. Seven subjects were studied, including five normals and two patients with heterozygous familial hypercholesterolemia; the latter had elevated LDL-cholesterol levels, tendinous xanthomata, and affected first-degree relatives. Subject D. L. also participated in study A.
Study C. Eight subjects were studied, including six normals and two patients with heterozygous familial hypercholesterolemia, five of whom were also included in study B. The diagnosis of familial hypercholesterolemia was based on elevated LDL-cholesterol levels, tendinous xanthomata, and affected first-degree relatives.
Clinical data for all the studies are summarized in Table I . Fully informed consent was obtained from all participants.
Preparation of radiolabeled lipoproteins
Blood was drawn from the subjects after a 14-h fast with 0.1% EDTA as an anticoagulant. VLDL was isolated at plasma density (d = 1.006) by ultracentrifugation for 16 h at 105,000 g (13) . The VLDL was then twice washed and concentrated by further ultracentrifugations at plasma density (d = 1.006) for 16 h each at 105,000 g.
Chylomicrons (Sf > 400) were removed before VLDL separation from plasma from patient B. W. (type V), by ultracentrifugation, 20,000 g for 30 min twice (14) .
Low density lipoproteins (LDL1 and LDL2) were isolated in the density range 1.006-1.063 and recentrifuged at a background density of 1.063 (13) for 20 h at 105,000 g.
The apoproteins of VLDL (apo B and apo C chiefly) were radioiodinated with 'I by the iodine monochloride (ICl) method of MacFarlane (15) , as modified for iodination of apolipoproteins by Langer et al. (16) . 1 M glycine: NaOH buffer at pH 10.0 and initial concentration of VLDL protein in the range of 5-15 mg/ml were used. If the molecular weight is 300,000 for the whole apo VLDL complex, the amount of ICI added was such that less than one atom of iodine was introduced per molecule of VLDL.
LDL was radioiodinated with 'I in the same way, after dialysis against 0.15 M NaCl solution containing 1 mM IIa EDTA at pH 7.4. The molecular weight of apo LDL was assumed to be 100,000. Unbound iodine was removed from the iodinated sample with a column of Sephadex G 10, suspended in sterile 0.15 M NaCl. The eluate was dialyzed against 0.15 M NaCl, 1 mM EDTA, pH 7.4. After dialysis the radioiodinated prel,arations contained less than 2%o unbound iodine, as determined by precipitation with 15% trichloroacetic acid (TCA) in the presence of carrier albumin.
As determined by ethanol/ether extraction (3: 1 vol/vol) (Scanu and Edelstein [17] ), 8-22% of radiolabeling in VLDL and less than 5% in LDL was in the lipid moiety. We confirmed that by this procedure 98%o of the lipid moiety is extracted. The fraction of apo VLDL soluble in 3: 1 ethanol/ether was precipitated by adding sufficient ether to bring the ethanol to ether ratio of the mixture to 3: 5 as these authors described.
Both the B and C peptide components of VLDL became labeled during the iodination procedure and 43-57% of radiolabeling in apo-VLDL was bound to B-peptide, as determined by Sephadex G 150 chromatography (18) (see study B). More than 95% of 'I radioactivity in the LDL dose (d 1.006-1.063) was in the density range 1.019-1.063 (LDL2) as determined by ultracentrifugal fractionation (13) , presumably reflecting the relative protein concentrations in the subjects studied.
The iodinated lipoproteins were sterilized by Millipore filtration (pore size 0.45 /AM) (Millipore Corp., Bedford,
Mass.).
A maximum of 96 h elapsed between the taking of the initial blood sample and reinjection of the labeled VLDL and LDL. The iodinated lipoproteins had the same mobility as native lipoproteins on cellulose acetate electrophoresis. The preparations were found to be free of albumin as determined by double immunodiffusion with antisera reacting against human serum albumin. After final dialysis, sterile human albumin was added to the iodinated preparation to minimize self-radiation.
Radioactivity was determined with a double-channel gamma spectrometer.
Study protocol
The sterile radiolabeled 'I-VLDL (total radioactivity uCi in approximately 1-5 mg of apoprotein) was reinjected i.v. on the morning after a 14-h fast. In studies B and C, radiolabeled 'I-LDL (total radioactivity [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] IACi in approximately 2-8 mg of apoprotein) was simultaneously injected i.v. For 12-30 h after the injection, blood samples (12 ml) were withdrawn at 2-3-h intervals, through an indwelling cannula. In study C further blood samples were taken daily for 2 wk.
During the first 24 h after the injection, the subjects received a diet containing 300 g of carbohydrate, 60 g of protein and less than 5 g of fat; this was to minimize change in caloric balance and to avoid intestinal VLDL synthesis. One patient (H. J.) received this diet for 48 h. Subsequently they received their normal free diet. Body weight remained steady (±-0.5 kg) during the 2 wk of study. The subjects received 180 mg of potassium iodide daily, by mouth, in divided doses for 4 days before and throughout the study, to inhibit uptake of radioiodine by the thyroid.
A further study was performed in two subjects with elevated serum triglyceride levels (part of study C). Autologous 'I-VLDL, in the presence of carrier albumin, (total dose 30 ,uCi in 5 mg of apoprotein) was infused i.v. at a constant rate after a priming dose. This infusion was continued overnight for 16 h; it was then stopped and a bolus i.v. injection of radiolabeled mI-VLDL (15 uCi) was given and the plasma disappearance curves of mI-VLDL-B and 'I-VLDL-B were compared.
Sample analysis
Determination of ''I-VLDL-B specific activity curve (Study A). The plasma was immediately separated at 4°C. VLDL was isolated by ultracentrifugation for 16 h at 105,000 g (13) and removed by tube slicing.
VLDL was delipidated by ethanol/ether and ether extraction (17) . To obtain purified B-peptide, the apoprotein precipitate was first washed with 0.2 M Tris HCl buffer, pH 8.2, to remove Tris-soluble peptides; the remaining insoluble material was then dissolved in 0.2 M Tris-HCl, pH 8.2, containing 0.1 M sodium decyl sulphate. This solution was subjected to Sephadex G 150 chromatography (column size 60 x 0.8 cm) (18) .
The fraction that corresponded to the maximum of the peak eluting at the void volume was collected for determination of VLDL-B peptide specific activity. The amino acid composition of this fraction was determined and compared to that of the corresponding peak obtained from Sephadex G 150 chromatography of delipidated and resolubilized LDL2 (d 1.019-1.063). A JEOL JLC 6AH amino acid analyzer (JEOL Analytic Instruments, Cranford, N. J.) was used. Compositions were expressed as moles of amino acid relative to aspartic acid= 100 mol. An average difference of 3.6%o was found between the amino acid composition of VLDL-B and LDL-B, purified as described above. No residues showed more than 10% difference. The mean amino acid composition differed by less than 5% from that published by Levy et al. for an LDL fraction of density 1.019-1.063 (19) . Thus the VLDL-B peptide obtained as above was considered to be virtually identical in amino acid composition with LDL-B peptide.
Protein concentrations of fractions containing VLDL-B peptide were determined by precipitation in 15% TCA followed by Amidoblack binding (20) . The method was sensitive down to protein concentrations of 5 ,ug/ml and was not affected by the presence of Tris or sodium decyl sulphate.
Determination of 13I-LDL-B specific activity curve. LDL was isolated from the infranate of the same plasma samples from which the VLDL was isolated. This was accomplished by centrifugation for 20 h at 105,000 g at a background density of 1.063 g/ml. The LDL fractions were carefully overlayered with a solution of density 1.063 g/ml and washed by recentrifugation under the same conditions. The 'I radioactivity in the washed LDL fractions and in the VLDL-B peptide fractions was determined at the same time. Radioactivity associated with the lipid and with the tetramethyl urea-soluble apoproteins (including C peptide) in LDL fractions was determined. This was subtracted from the total radioactivity. Lipid-associated radioactivity was assayed by ethanol-ether extraction (17) . Radioactivity associated with soluble apoproteins in LDL was assayed in the aqueous phase after tetramethyl urea precipitation (21) ; this was found to be less than 5% of the total radioactivity except in the samples taken during the first 3-4 h. The protein concentration of the LDL fractions was determined by TCA precipitation and Amidoblack binding, as described for VLDL-B peptide.
In calculating the specific activity, the radioactivity (minus the lipid and soluble apoprotein contributions) was divided by the Samzple analysis (stutdy, B). A fraction of the '31I-VLDL dose was delipidated (17) and fractionated with Sephadex G 150 (18) . The fraction of the dose injected as "'I-VLDL-B was thus obtained.
The recovery of radioactivity from the column was about 80%. The recovery rate was the same for B and C peptides (as demonstrated by reapplication of the eluted fractions oln to new columns); the error introduce(d hy the incoilmplete recovery was therefore consi(lered minimilal, and not selective for either peptide.
VLDL and LDL fractions from the plasma samples were isolated by ultracentrifugation (13) . Total "3'I and '25I radioactivity in the LDL fractions wvere determined simultaneously along wvith appropriate stan(lar(ls. The quenching of '2'I (due to high salt conicentrationi was correcte(l for, with Na1251 as internial standar(l. The LD)L fractions were delipidated (ethaniol/ether 3: 1 vol/vol) (17) and the radioactivity in the lipid moiety wvas subtracted from the total counts. The radioactivity bound to soluble apoproteins in the LDL fractions was determined as described in study A and subtracted. The 13'I and 125J radioactivity in LDL-B Sample anialysis (stuidy, C). VLDL-B peptide was isolated and specific activity/timne curves obtained as described in study A. Total V'LDL-B peptide concentration in plasma was determined by tetraimiethylurea precipitation on respun VLDL fractions as described by Kane (21) . Protein estimations were carried out by the method of Lowry et al. (23) (25) . The points of intersectioni of the cuirves for \LD)L-B peptide andlI )DL-B peptidle wer-e observed (Fig. 1) . Zilversmnit has shown that if a product receives its A atoms only fromn one immediate precursor (w,N-hich has been labeled) the values of the specific activity curve for the product will lie below the values of the curve for the precursor until the specific activity curve for the product reaches its maximum. At the maximum the curves will intersect, the product curve thereafter lying above the curve for the immediate precursor. But if the product receives its A atomis from any other source in addition to the labeled precursor, the curve for the product vill remaiin below the curve for the precursor at least for some time after the curve for the product has reached its maximiluIml; depending on the parameters of the system the curves may or may not evenitually cross (25) .
Intersection of specific activity curves is thus compatible with a precursor-product relationship but does not prove it. For example, if A is the precursor of B, but C is in rapid equilibrium with A, theni the specific activity curve for C would also cross that for B anid yet C would not be a precursor (26 (27) R(t) = f I(T) -T(t-T)dT 1(t) (the unknown input function) is the transfer function of '31I-VLDL-B into '31I-LDL-B; R(t), the known response function to the input fuinction I(t) equals '31I-LDL-B curve (which reflects both the appearance of 13"I into the LDL-B pool and the disappearance fromn this pool) ; W(t) (the know-n weighting function) equals 5I-LDL-B curve; T is the age variable of integration (Fig. 2) .
By inserting the values of the functions I(t) and W(t) obtained from appropriate curves (see Methods) we obtaine I ( t), whose integral gave the fraction of dose injected as 1"I-VLDL-B which had been converted into 'I-
LDL-B.
This technique is based on the assumption that the fractional removal rate is the same for "3'I-LDL-B and '251-lJ)L-B. The validity of this assumption is supported by thie p)arallelism of the disappearance curves of these isotopes in LDL (Fig. 2) .
The mean conversion time (t), i.e. the mean time required for VLDL-B molecule to become an LDL-B molecule, is given by (28) :
Computation of data was performed on a digital computer, with the discrete formulation of the equation described by Stephenson (29) with a program similar to that of Hart and Spencer (30) .
Alternatively the fraction of VLDL-B converted into LDL-B may be calculated if the 'I-LDL-B curve is regarded conceptually as reflecting 100% conversion into LDL (as it was injected in this form). The ratio of the isotope doses remaining, 13ll-LDL-B %c dose (of "31I-VLDL-B)/liter plasma 125I-LDL-B, % dose/liter plasma when the curves have become parallel, therefore gives the fraction of radiolabeled VLDL-B dose converted into LDL. Allowance was made for the fact that the injected 'I-LDL-B had been in the circulation longer than "I-LDL-B, the latter was being synthesized from 'I-VLDL-B. The ratio was calculated by taking the value of 'I-LDL-B at t1 but taking the corresponding l"I-LDL-B value at time t1 + t (the mean conversion time for the particular subject).
Stuidy C. When the specific activity-time curve for 13lI-VLDL-B after a bolus injection is plotted semilogarithmically, the curve appears to be monoexponential for at least 3-4 half-lives (Fig. 3) , during which time most of labeled B peptide enters LDL (study B). By the time that the second exponential appears, at the most 10% of the injected dose remains in VLDL-B peptide. Therefore the fractional There is no evidence that B peptide recycles from LDL arance curve (upper to VLDL. Injected radiolabeled 'I-LDL remains in the curve, reflecting ap-LDL fraction and is not found to any extent in the VLDL )L-B and disappear-fraction (16) . However, as the LDL-B pool turns over :ne subject (D. L.). relatively slowly compared to the rapid turnover of VLDL-B, a minor recycling cannot be ruled out; this might contribute to the long half-life of later exponentials of the 'I-VLDL-B curve.
The plasma volume (in liters) was assumed as 4.5% of body weight (32) and the total intravascular VLDL-B pool was then calculated as the product of VLDL-B concentration and the plasma volume. The steady state synthetic rate of VLDL-B (or absolute catabolic rate) was calculated as follows: synthetic rate = FCR X intravascular VLDL-B peptide.
The synthetic rate was expressed as milligrams of VLDL-B peptide synthesized per 24 h, normalized for body weight (milligrams per kilogram per 24 h).
The fraction of the intravascular LDL-B peptide pool catabolized per day (FCR) was calculated by analysis of plasma decay curve of 'mI-LDL-B injected i.v. by methods described by Matthews (33) . The LDL-B peptide concentration in plasma was determined by the method of Lowry et al. (23) on recentrifuged LDL fractions. Correction for incomplete recovery of lipoproteins was based on measurements of cholesterol concentration before and after recentrifugation. The same correction factor (0.77) was used as for estimation of VLDL-B peptide. The total intravascular pool of LDL-B peptide was calculated from the product of LDL-B peptide concentration in plasma and the plasma volume (by the same volume as for VLDL-B turnover). This assumed volume was within ±5% of the volume obtained by isotope dilution method by measuring radioactivity in samples taken 10 min after injection.
The steady state synthetic rate of LDL-B peptide was then calculated in the same way as that of VLDL-B peptide: synthetic rate = FCR X intravascular LDL-B peptide, (milligrams/kilogram per day).
The metabolic homogeneity of radiolabeled '1I-LDL was assessed from the daily urinary radioactivity excretion from day 2 to day 8 of each study, by the metabolic clearance method of Berson and Yalow (34) . With this method the clearance of 1'I-LDL was calculated for each day of study from the ratio of total urinary radioactivity excreted per day to the mean plasma radioactivity during the interval (U/P ratio).
RESULTS
Study A. Fig. 1 shows the specific activity-time curves for '31I-VLDL-B and '=I-LDL-B for a representative subject (J. K.). The curves in the other six subjects showed a very similar pattern, i.e., they appeared to intersect at the maximum of the product curve, ''I-LDL-B. Table II shows the time course of this intersection, which was directly related to the VLDL-triglyceride concentration of these subjects (r = + 0.86, P <0.02) and to the half-life of 'I-VLDL-B in plasma (r = + 0.87, P < 0.02). It did not bear any relationship to the LDL-cholesterol concentration.
Study B. Table III shows in column a the fraction of dose injected as 'I-VLDL-B that was converted into u1I-LDL-B, calculated by integration of function I (t); the fraction appearing in column b is the ratio of 'I-LDL-B to 'I-LDL-B after the curves had become parallel (corrected for the mean conversion time). Both methods gave similar results.
Column c shows the mean conversion time of VLDL-B into LDL-B. The mean conversion time was proportional to the VLDL-triglyceride concentration (r = + 0.76, P <0.05).
Samples were obtained from one subject (H. J.) for 48 h after the injection. Subfractions of density ranges 1.006-1.019 and 1.019-1.063 were obtained by further ultracentrifugation (13) and analyzed separately. By the same methods of calculation it was found that 0.84 (method a) and 0.86 (method b) of the dose injected as 'I-VLDL-B was recovered in the LDL fraction 1.019-1.063. The mean conversion time into LDL fraction 1.019-1.063 was 15.8 h, compared to 7.6 h into LDL fraction 1.006-1.063. Study C. VLDL-triglyceride and VLDL-B concentrations remained within ±+10% of the initial fasting value during the time of VLDL-B turnover study (12-24 h ). Fasting LDL-cholesterol levels remained within ±8% of the initial fasting value and the cholesterol to protein ratio remained constant during the 2 wk of study.
Body weight remained steady (±0.5 kg) during the 2 wk of study. The turnover rate of VLDL-B peptide ranged from 9.7 to 19.7 mg/kg/day, with a mean value of 14.53±
3.18 mg/kg/day (SD). The LDL-B peptide turnover ranged from 8.75 to 14.24 mg/kg/day, with a mean of 11.94±1.96 mg/kg/day (Table IV) .
The half-lives of the plasma disappearance curves for 'I-VLDL-B (after an i.v. bolus injection) and 'I-VLDL-B were compared. The latter was determined after stopping a constant infusion continued for 16 h, by which time a plateau for the specific activity for 'I-VLDL-B had been reached. The half-lives were 9.3 h and 8.6 h for I and =I, respectively, in one patient, and 4.1 h and 3.9 h in the other (Fig. 4) . ' The turnover rate of VLDL-B peptide, as determined by the formula: [Rate of infusion of 'I-VLDL-B (in dpm/h)/Specific activity of plasma 'I-VLDL-B at equilibrium (in dpm/mg B peptide)], was within ±5% of the turnover rate obtained by a bolus injection of JI-VLDL-B.
As study B indicated that most of the VLDL-B is converted into LDL-B peptide, the mean conversion time (t) (study B) should be similar to the mean turnover time of VLDL-B peptide in the circulation. VLDL-B turnover rate can be calculated from: VLDL-B turnover (in mg)=[24 h/F (in h)]X i.v. pool size of VLDL-B (in mg). Table V shows a comparison of VLDL-B turnover data in five subjects included in both study B and C; in column a the turnover rate is derived from the mean conversion time (study B) and in column b from specific activity curves (study C). The two methods gave The FCR for LDL-B pepticle, calcalated fromii the plasma curve, was slightly highler thani that derived from the mean U/P ratio. The _U P ratio x-as observed for 7 days; it remaiined constant, after the initial delav in excretion due to a retention of 12-' within the iodide pool (16) , indicating that no significant amiiounlt of rapidly degradable protein had been pr-esenit.
No direct test of the imietabolic integrity of radioiodinated VLDL is available, since the proteiilnmoiety is lheterogeneous. Biologic sci-eeninig is difficult due to the rapid turnover of V'LDL anid its promlpt coniversioni to LDL. But as the rate of removal of radiolabeled`31J-LDL-B (coniceptually corresponding to enldogenously labeled LDL) was the same as for "I-LDL-B (Fig. 2) and as the lU/P ratio for I'J-LDL remaiined constant. this wsould indirectly suggest a metabolic homiiogenieity, at least for that part of radiolabeled V-LDL-B converted into LDL-B.
DISCUSSION
Stuidies of specific activity ciurvcs for-apo B in VlDL anid LDL (stutdy A). The intersectioni of the specific activity-time curves of VLDL-B and LDL-B at the maximum of the curve for LDL-B suggests that most if not all LDL-B peptide (under the experimiiental conditions) is derived from VLDL-B peptide. This occurred in normal subjects, patients w-ith endogenous hypertriglyceridemia and in onie patient with heterozygous familial hyperclholesterolemiiia. The same conclusion has been suggested by previous studies (7, 11. 35) . but not on the basis of specific activity-time curves.
In the present study the density range 1.006-1.063 was used in the isolation of LDL to include all B peptide within LDL. Lee and Alaupovic (10) have slhowsn that the apoprotein of density ranige 1.006-1.019 contains about 3040%/ C peptide. The total apoprotein concenitration of density range 1.006-1.019 in the subjects studied was only a small fraction of the total apop)rotein concentration of the whole LDL densitv range of 1.006-1.063; the small anmount of C peptide included shotuld therefore introduce onlv a minor error into the measuiremiient of specific activity for '25I-LDL-B. This is also supported by the finding that the method used gave specific activity values closely similar (±6%r, ) to (39, 40) . This could explain the low concentration of LDL in rats compared with humans.
14SS
Mlost of radiolabeled VLDL-B peptide was recovered in the LDL fraction 1.019-1.063 in the subject in whom this was quantitated. This may be different in hyperlipidemic subjects; Hall et Of the eight subjects studied, four showed closely similar synthetic rates for VLDL-B and LDL-B (leEs than 5% difference). In the other subjects VLDL-B turnover was higher than that of LDL-B; this conceivably reflects a true biological heterogeneity, but it is possible that the discrepancy results from purely analytical factors. It is evident from Kane's data (21) that the tetramethylurea precipitate may include a trace of protein other than apo B. Resultant overestimation of VLDL-B pool size would lead to a magnified error in estimating synthetic rate of VLDL-B peptide, as the pool is turned over several times per day. It is to be noted that VLDL-B turnover was measured on a very low fat diet when no chylomicrons were circulating. One could therefore not exclude that chylomicrons might (under other nutritional circumstances) contribute to the production of LDL-B. The observation that LDL-B turnover, measured during 2 wk of normal free diet, was still similar to the VLDL-B turnover would make this possibility unlikely.
For the estimation of LDL-B turnover, the density range 1.006-1.063 g/ml was used to obtain the total turnover rate of LDL-B peptide. Lee (16) .
